이 기사의 번역을 준비하고 있습니다. 그동안 영어 원문을 임시로 표시합니다.
비즈니스 · 1997. 11. 20.1 분 읽기
Urologix, Inc.; Premarket Approval of the T3Register Targeted Transurethral Thermoablation System: Model 4000
로컬 자동 번역 · 원본 출처 언어
요약
The Food and Drug Administration (FDA) is announcing its approval of the application by Urologix, Inc., Minneapolis, MN, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of the T3 Targeted Transurethral Thermoablation System: Model 4000. FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of August 22, 1997, of the approval of the application.
원본 출처 언어: Federal Register — Food and Drug Administration원문 발표 열기 →